Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics

Haematologica

Volumn 99, Issue 7, 2014, Pages 1239-1247

  Vrana, Julie A ^a   Theis, Jason D ^a   Dasari, Surendra ^a   Mereuta, Oana M ^a,b   Dispenzieri, Angela ^a   Zeldenrust, Steven R ^a   Gertz, Morie A ^a   Kurtin, Paul J ^a   Grogg, Karen L ^a   Dogan, Ahmet ^a,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; AMYLOID A PROTEIN; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; COLLAGEN; GELSOLIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; INSULIN; LIPOCORTIN 2; LYSOZYME; MYOSIN; PERILIPIN; PREALBUMIN; SERUM AMYLOID A; VIMENTIN; AMYLOID; APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV; IMMUNOGLOBULIN LIGHT CHAIN; SERUM AMYLOID P;

ABDOMINAL FAT ASPIRATION BIOPSY; ADULT; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEOMICS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; AMYLOID NEUROPATHIES, FAMILIAL; BLOOD; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEEDLE BIOPSY; PATHOLOGY; SUBCUTANEOUS FAT;

ADULT; AGED; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; APOLIPOPROTEINS A; APOLIPOPROTEINS E; BIOPSY, NEEDLE; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUTATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID P-COMPONENT; SUBCUTANEOUS FAT;

EID: 84903649455     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.102764     Document Type: Article

References (50)

1. Gertz MA, Kyle RA. Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc. 1989;64(12):1505-19.
2. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma. 2005;6(3):208-19.
3. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14): 1924-33.
4. Westermark P, Stenkvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med. 1973;132(4):522-3.
5. Gertz MA, Li CY, Shirahama T, Kyle RA. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Intern Med. 1988;148(4):929-33.
6. Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med. 1983;143(8):1549-52.
7. Duston MA, Skinner M, Meenan RF, Cohen AS. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum. 1989;32(1):82-5.
8. van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015-21.
9. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-9.
10. Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, et al. Mass spectrometricbased proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195-9.
11. Chee CE, Lacy MQ, Dogan A, Zeldenrust SR, Gertz MA. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk. 2010;10(3):177-80.
12. Sethi S, Theis JD, Leung N, Dispenzieri A, Nasr SH, Fidler ME, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol. 2010;5(12):2180-7.
13. Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, et al. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol. 2011;35(11):1685-90.
14. Valleix S, Gillmore JD, Bridoux F, Mangione PP, Dogan A, Nedelec B, et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin. N Engl J Med. 2012;366(24):2276-83.
15. Sethi S, Vrana JA, Theis JD, Leung N, Sethi A, Nasr SH, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012;82(2):226-34.
16. Maleszewski JJ, Murray DL, Dispenzieri A, Grogan M, Pereira NL, Jenkins SM, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013;22(3):189-94.
17. D'Souza A, Theis J, Quint P, Kyle R, Gertz M, Zeldenrust S, et al. Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. Am J Hematol. 2013;88(7):577-80.
18. Grogg KL, Aubry MC, Vrana JA, Theis JD, Dogan A. Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol. 2013;37(3):406-12.
19. Said SM, Reynolds C, Jimenez RE, Chen B, Vrana JA, Theis JD, et al. Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. Mod Pathol. 2013;26(2):232-8.
20. Westermark P, Benson L, Juul J, Sletten K. Use of subcutaneous abdominal fat biopsy specimen for detailed typing of amyloid fibril protein-AL by amino acid sequence analysis. 1989;42(8):817-9.
21. Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid. 2007;14(2):133-40.
22. Vrana JA, Zeldenrust SR, Theis JD, Gamez JD, Kurtin PJ, Dogan A. Diagnosis and classification of amyloidosis in abdominal subcutaneous fat aspiration specimens using mass spectrometry based proteomics. Blood. 2008;112(11):937.
23. Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Théberge R, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics. 2008;7 (8):1570-83.
24. Lavatelli F, Valentini V, Palladini G, Verga L, Russo P, Foli A, et al. Mass spectrometrybased proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid. 2011;18 (Suppl 1):64-6.
25. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119(8):1844-7.
26. Westermark P, Davey E, Lindbom K, Enqvist S. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem. 2006;108(3):209-13.
27. Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom. 1994;5(11):976-89.
28. Fenyo D, Beavis RC. A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. Anal Chem. 2003; 75(4):768-74.
29. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20 (18):3551-67.
30. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006-12.
31. Elias JE, Haas W, Faherty BK, Gygi SP. Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods. 2005;2(9):667-75.
32. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51(5):878-81.
33. Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc. 2002;77 (12):1287-90.
34. Nagase T, Katsura Y, Iwaki Y, Nemoto K, Sekine H, Miwa K, et al. The insulin ball. Lancet. 2009;373(9658):184.
35. Yumlu S, Barany R, Eriksson M, Rocken C. Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol. 2009;40(11):1655-60.
36. Albert SG, Obadiah J, Parseghian SA, Yadira Hurley M, Mooradian AD. Severe insulin resistance associated with subcutaneous amyloid deposition. Diabetes Res Clin Pract. 2007;75(3):374-6.
37. Endo JO, Rocken C, Lamb S, Harris RM, Bowen AR. Nodular amyloidosis in a diabetic patient with frequent hypoglycemia: sequelae of repeatedly injecting insulin without site rotation. J Am Acad Dermatol. 2010;63(6):e113-4.
38. D'Souza A, Theis JD, Vrana JA, Buadi F, Dispenzieri A, Dogan A. Localized insulinderived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol. 2012;87(11):E131-2.
39. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98(3):714-20.
40. Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002;100(3): 948-53.
41. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801-8.
42. Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest. 1989;83(3):836-43.
43. Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest. 1986;78(1):6-12.
44. Uemichi T, Gertz MA, Benson MD. A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy. J Med Genet. 1995;32(4):279-81.
45. Ueno S, Uemichi T, Takahashi N, Soga F, Yorifuji S, Tarui S. Two novel variants of transthyretin identified in Japanese cases with familial amyloidotic polyneuropathy: transthyretin (Glu42 to Gly) and transthyretin (Ser50 to Arg). Biochem Biophys Res Commun. 1990;169(3):1117-21.
46. Reilly MM, Adams D, Booth DR, Davis MB, Said G, Laubriat-Bianchin M, et al. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain. 1995;118(Pt 4):849-56.
47. Jones LA, Skare JC, Cohen AS, Harding JA, Milunsky A, Skinner M. Familial amyloidotic polyneuropathy: a new transthyretin position 30 mutation (alanine for valine) in a family of German descent. Clin Genet. 1992;41(2):70-3.
48. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66(2): 229-33.
49. Nichols WC, Liepnieks JJ, McKusick VA, Benson MD. Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics. 1989;5(3):535-40.
50. Uemichi T, Liepnieks JJ, Benson MD. A trinucleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy. Neurology. 1997;48(6):1667-70.